Enovis (ENOV) vs TriMas (TRS)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
TriMas (TRS) has outperformed Enovis (ENOV) over the past year, gaining 2.9% versus a loss of 45.2%. Over five years, TRS leads with a +22.3% price change compared with -80.0% for ENOV. TriMas is the larger company by market cap ($1.38 billion vs $1.01 billion), about 1.4 times the size.
On valuation, Enovis trades at a lower forward P/E (4.9x vs 18.1x for TriMas). TriMas pays a dividend yielding 0.42%, while Enovis does not currently pay one.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ENOV | TRS |
|---|---|---|
| Share price | $17.43 | $38.44 |
| Market cap | $1.01B | $1.38B |
| 1-day change | -1.02% | +0.50% |
| YTD return | -34.57% | +8.43% |
| 1-year return | -45.15% | +2.89% |
| 5-year return | -79.99% | +22.30% |
| P/E ratio (TTM) | — | 15.63 |
| Forward P/E | 4.85 | 18.06 |
| EPS (TTM) | $-19.23 | $2.46 |
| Dividend yield | 0.00% | 0.42% |
| Annual dividend | $0.00 | $0.16 |
| 52-week high | $34.28 | $45.43 |
| 52-week low | $16.70 | $30.43 |
| Distance from 52-week high | -49.15% | -15.39% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +115.61% | +17.07% |
| Average volume | 1.45M | 366.31K |
| Shares outstanding | 57.67M | 35.87M |
| Employees | 7,802 | 2,500 |
| Sector | Healthcare | Industrials |
| Industry | Medical Devices | Industrial Specialties |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TRS has outperformed ENOV by 48.0 percentage points over the past year.
- The two companies sit in different sectors: Enovis in Healthcare and TriMas in Industrials.
About Enovis
ENOV stock →Enovis Corporation, a medical technology company, focuses on developing clinically differentiated solutions in the United States and internationally. It operates through two segments: Prevention and Recovery, and Reconstructive segments.
Healthcare · Medical Devices · 7,802 employees
About TriMas
TRS stock →TriMas Corporation engages in the design, development, manufacture, and sale of products for consumer products, aerospace and defense, and industrial markets worldwide. The company operates through Packaging and Specialty Products segments.
Industrials · Industrial Specialties · 2,500 employees
ENOV vs TRS FAQ
Which is bigger, Enovis or TriMas?
TriMas (TRS) is larger, with a market capitalization of $1.38B compared with $1.01B for Enovis (ENOV).
Which stock has performed better over the past year, ENOV or TRS?
TRS returned +2.89% over the past 12 months, compared with -45.15% for ENOV (price return, excluding dividends). Past performance does not predict future results.
Which pays a higher dividend, Enovis or TriMas?
TriMas pays a dividend yielding 0.42%, while Enovis does not currently pay a regular dividend.
Are Enovis and TriMas in the same industry?
No. Enovis is in the Healthcare sector, while TriMas is in Industrials.